lorlatinib
FDA Expands Approval of Pfizer's Lorbrena to First-Line ALK-Positive NSCLC; Approves Roche CDx
Based on full approval from the FDA based on the Phase III CROWN trial, Pfizer can now market the drug as a front-line option for ALK-positive NSCLC patients.